Browse > Article
http://dx.doi.org/10.15188/kjopp.2021.10.35.5.199

Review on the Objective Effect and Mechanism Studies of Herbal Medicine, Acupuncture and Moxibustion Treatment for Irritable Bowel Syndrome Patients  

Noh, Hyun Deok (Department of Korean Medicine, School of Korean Medicine, Pusan National University)
Kim, Min Jeong (Department of Korean Medicine, School of Korean Medicine, Pusan National University)
Cho, Im Hak (Department of Korean Medicine, School of Korean Medicine, Pusan National University)
Kim, So Yeon (Department of Korean Medicine, School of Korean Medicine, Pusan National University)
Publication Information
Journal of Physiology & Pathology in Korean Medicine / v.35, no.5, 2021 , pp. 199-209 More about this Journal
Abstract
The purpose of this study was to explore objective indicators(outcomes) which are used to evaluate clinical efficacy and figure out the mechanisms of herbal medicine, acupuncture and moxibustion treatment for Irritable bowel syndrome(IBS). We searched randomized controlled trials(RCTs) that mediated with herbal medicine, acupuncture and moxibustion treatment for IBS and used objective indicators for outcome from November 1, 2020 to December 31, 2020. The RCTs that were published in Korean, English and Chinese were included in this study. The selected literatures were analyzed about methods of result measurement and assessed by Cochrane's risk of bias(RoB). Total 18 RCTs were included in this study. There were lots of objective indicators for result measurement; the concentration of hormones in blood and neurotransmitters, the sensitivity of rectum, the functional assessment of central nerve and autonomic nerve system, the change of intestinal flora, the concentration of serum cytokines. Various objective indicators can be used to evaluate the clinical efficacy of with herbal medicine, acupuncture and moxibustion treatment for IBS, but due to the limitations of the quality of the included studies, systematic review and meta-analysis will be needed.
Keywords
Irritable bowel syndrome; Objective indicators; Herbal medicine; Acupuncture; Literature review;
Citations & Related Records
연도 인용수 순위
  • Reference
1 W Wilson D, PS Hungin A, H Howse J, De Meester F, B Singh R, Wilczynska A, et al. Role of hormones and neuropeptides in IBS and other gastrointestinal disorders: understanding variability and chrononutrition. The Open Nutraceuticals Journal. 2011;4(1).
2 Zhan DW, Sun JH, Luo KT, Xu LZ, Zhou JL, Pei LX, et al. Effects and efficacy observation of acupuncture on serum 5-HT in patients with diarrhea-predominant irritable bowel syndrome. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2014;34(2):135-8.
3 Liu YC. Clinical study of ascending-descending acupuncture method regulation of the spleen and stomach for treatment of Spleen Deficiency-type diarrhea in irritable bowel syndrome. Shanghai journal of acupuncture and moxibustion [shang hai zhen jiu za zhi]. 2015;34(1):25-7.
4 Liu-xiang H, Zhen L, Ling L. Effects of Tongxie Anpi Decoction Combined with Trimebutine Maleate Tablets on Serum 5-HT and CGRP in Patients with Diarrhea-predominant Irritable Bowel Syndrome with Hepatic Stagnation and Splenic Deficiency Chinese Journal of Experimental Formulas. 2016;22(05):188-91.
5 Wang SS, Wang XR, Yang RY, Xu Y, Li MY. Efficacy and mechanism of acupuncture combined with Tongxieyaofang for diarrhea-type irritable bowel syndrome of liver depression and spleen deficiency. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2020;40(6):605-9.
6 Zhao J, Li H, Shi C, Yang T, Xu B. Electroacupuncture inhibits the activity of astrocytes in spinal cord in rats with visceral hypersensitivity by inhibiting P2Y1 receptor-mediated MAPK/ERK signaling pathway. Evidence-Based Complementary and Alternative Medicine. 2020;2020.
7 Su-ping Y, Hui Y, Nan-lin H, Shu-qing D, Gao C. Effect of modified Sinisan on anorectal manometry of the constipation predominant type of irritable bowel syndrome. Chinese journal of integrative medicine. 2005;11(1):27-30.   DOI
8 Schneider A, Weiland C, Enck P, Joos S, Streitberger K, Maser-Gluth C, et al. Neuroendocrinological effects of acupuncture treatment in patients with irritable bowel syndrome. Complementary therapies in medicine. 2007;15(4):255-63.   DOI
9 Gao W, Wang C, Lin Y. Effect of jianpi tiaogan wenshen recipe in treating diarrhea-predominant irritable bowel syndrome. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi= Chinese journal of integrated traditional and Western medicine. 2010;30(1):13-7.
10 Shen J, Zhu Q, Yuan Y. Effect of changji'an oral liquid on activated signal alterative intensity in algesthesia domain in patients with diarrhea type irritable bowel syndrome due to gan-pi disharmony. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi=Chinese journal of integrated traditional and Western medicine. 2005;25(11):967-70.
11 Xing-xing Z, Jian W, Li-xia P, Yi X, Bai Y, Shen-lin L. Efficacy of Jianpi Shugan Fomula on Intestinal Flora of Patients with Diarrhea Predominant Irritable Bowel Syndrome and Its Effect on Intestinal Flora. Chinese Journal of Experimental Formulas. 2019;25(13):79-86.
12 Aziz I, Tornblom H, Palsson OS, Whitehead WE, Simren M. How the change in IBS criteria from Rome III to Rome IV impacts on clinical characteristics and key pathophysiological factors. American Journal of Gastroenterology. 2018;113(7):1017-25.   DOI
13 Lowe C, Aiken A, Day AG, Depew W, Vanner SJ. Sham acupuncture is as efficacious as true acupuncture for the treatment of IBS: A randomized placebo controlled trial. Neurogastroenterology and Motility. 2017;29(7).
14 Wu XL, Wang YL, Sun JH, Shu YY, Pei LX, Zhou JL, et al. Clinical observation on acupuncture for diarrhea-predominant irritable bowel syndrome patients in syndrome of liver-stagnation and spleen-deficiency and its impact on Th1/Th2. Zhongguo zhen jiu [Chinese acupuncture & moxibustion]. 2013;33(12):1057-60.
15 Runhong Z. The effect of accupuncture-moxibustion treatment on serum IL-18, IL-23 and TNF-α level of elderly people with IBS. Chinese Journal of Gerontology. 2013;33(06):1435-6.
16 Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, et al. Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea. Scand J Gastroenterol. 2014;49(1):43-51.   DOI
17 Yuan Y-Z, Tao R-J, Xu B, Sun J, Chen K-M, Miao F, et al. Functional brain imaging in irritable bowel syndrome with rectal balloon-distention by using fMRI. World journal of gastroenterology: WJG. 2003;9(6):1356.   DOI
18 Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. 2014.
19 Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krogius L, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. American Journal of Gastroenterology. 2005;100(2):373-82.   DOI
20 Bergman RA AA, Heidger PM. Plate 6.111 Vasoactive Intestinal Polypeptide (VIP) www.anatomyatlases.org2009-02-06
21 Qin G, Zhang Y, Yao SK. Serotonin transporter and cholecystokinin in diarrhea-predominant irritable bowel syndrome: Associations with abdominal pain, visceral hypersensitivity and psychological performance. World J Clin Cases. 2020;8(9):1632-41.   DOI
22 El-Salhy M, Lillebo E, Reinemo A, Salmelid L. Ghrelin in patients with irritable bowel syndrome. International journal of molecular medicine. 2009;23(6):703-7.
23 YT P. Anorectal funtion test. Korean Journal of Neurogastroenterology and Motility. 1999;5(2).
24 Dunlop SP, Coleman NS, Blackshaw E, Perkins AC, Singh G, Marsden CA, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clinical Gastroenterology and Hepatology. 2005;3(4):349-57.   DOI
25 Kerckhoffs APM, Samsom... M. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. 2009.
26 Bashashati M, Rezaei N, Shafieyoun A, McKernan D, Chang L, Ohman L, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterology & Motility. 2014;26(7):1036-48.   DOI
27 Yanqing L, Zhang H, Zuo X. Study on the shifting of Th1/Th2 balance of large intestinal mucosa in patients with irritable bowel syndrome. Chinese Journal of Digestion. 2001(12).
28 Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, et al. Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea. Scandinavian journal of gastroenterology. 2013;49(1):43-51.   DOI
29 Sun X, Cai G, Wang W-J. Observation on intestinal flora in patients of irritable bowel syndrome after treatment of Chinese integrative medicine. Zhong xi yi jie he xue bao= Journal of Chinese integrative medicine. 2004;2(5):340-2.
30 Sood R, Law GR, Ford AC. Diagnosis of IBS: symptoms, symptom-based criteria, biomarkers or'psychomarkers'? Nature Reviews Gastroenterology & Hepatology. 2014;11(11):683.   DOI
31 Cong L. Clinical Observation on Acupuncture Combined with Thunder-Fire Moxibustion in Treating IBS of Spleen-Deficiency Diarrhea. Journal of Chinese Medicine. 2020;48(03):56-60.
32 Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2006;130(1):34-43.   DOI
33 Chang SJ, Kim JH, Min SY. A PubMed Literature Study of Korean Medicine Treatment (Acupuncture) in Irritable Bowel Syndrome. The journal of pediatrics of Korean medicine. 2018;32(3):119-30.   DOI
34 Chu WCW, Wu JCY, Yew DTW, Zhang L, Shi L, Yeung DKW, et al. Does acupuncture therapy alter activation of neural pathway for pain perception in irritable bowel syndrome?: A comparative study of true and sham acupuncture using functional magnetic resonance imaging. Journal of Neurogastroenterology and Motility. 2012;18(3):305-16.   DOI
35 Han CW, Choi J-Y, Park SH, Kim SY. Experimental Study Trends on the Acupuncture Moxibustion Treatment for Visceral Hypersensitivity: Based on the Data of PubMed. Korean Journal of Acupuncture. 2019;36(2):93-103.   DOI
36 Foxx-Orenstein A. IBS-review and what's new. Medscape General Medicine. 2006;8(3):20.
37 Meizhe P, Siyu W, Xiang L, Si C, Wei L, Peiyi Z, et al. The Clinical and Experimental Study on Soothing Liver and Trengthening Spleen Intervention of Diarrhea-predominant Irritable Bowel Syndrome. World Traditional Chinese Medicine. 2014;9(12):1595-8.
38 Acosta A, Camilleri M, Linker-Nord S, Busciglio I, Iturrino J, Szarka LA, et al. A Pilot Study of the Effect of Daikenchuto on Rectal Sensation in Patients with Irritable Bowel Syndrome. J Neurogastroenterol Motil. 2016;22(1):69-77.   DOI
39 Hyun Sul Kim, Kim BJ. Latest Research Trends of Korean Medicine for the Treatment of Gastrointestinal Diseases. Korean J Oriental Physiology & Pathology. 2013;27(5):570-7.
40 Dae-Seog H, Soo-Young K, Ji-Eun P, Hyun-Ju S, Yoon-Jae L, Hee-Jung S, et al. NECA's guidance for undertaking systematic reviews and meta-analyses for intervention. research report. 2015;1(1):1-287.
41 Zhang H, Yan Y, Shi R, Lin Z, Wang M, Lin L. Correlation of gut hormones with irritable bowel syndrome. Digestion. 2008;78(2-3):72-6.   DOI
42 Si J-M, Yu Y-C, Fan Y-J, Chen S-J. Intestinal microecology and quality of life in irritable bowel syndrome patients. World journal of gastroenterology: WJG. 2004;10(12):1802.   DOI
43 Chen-er Z, Feng P, Tao Z. A Clinical Study on Banxia Xiexin Decoction Treating Diarrhea Predominated Irritable Bowel Syndrome by Observing the Expression of Ghrelin. Chinese Journal of Traditional Chinese Medicine. 2011;29(11):2588-91.
44 Bearcroft C, Perrett D, Farthing M. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut. 1998;42(1):42-6.   DOI
45 Houghton L, Atkinson W, Whitaker R, Whorwell P, Rimmer M. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut. 2003;52(5):663-70.   DOI
46 Jones M, Chey W, Singh S, Gong H, Shringarpure R, Hoe N, et al. A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Alimentary pharmacology & therapeutics. 2014;39(4):426-37.   DOI
47 Lembo A, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Alimentary pharmacology & therapeutics. 2009;29(8):834-42.   DOI
48 Krejs GJ, Fordtran JS, Fischer J, Humphrey C, O'Dorisio T, Said S, et al. Effect of VIP infusion on water and ion transport in the human jejunum. Gastroenterology. 1980;78(4):722-7.   DOI
49 Love J, Szurszewski J. The electrophysiological effects of vasoactive intestinal polypeptide in the guinea-pig inferior mesenteric ganglion. The Journal of physiology. 1987;394(1):67-84.   DOI
50 Palsson OS, Morteau O, Bozymski EM, Woosley JT, Sartor RB, Davies MJ, et al. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Digestive diseases and sciences. 2004;49(7):1236-43.   DOI
51 Simren M, Stotzer P-O, Sjovall H, Abrahamsson H, Bjornsson ES. Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome. European journal of gastroenterology & hepatology. 2003;15(1):55-62.   DOI
52 Iwasaki M, Akiba Y, Kaunitz J. Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system [version 1; peer review: 4 approved]. F1000Research. 2019;8(1629).